Intramuscular ketamine vs. midazolam for rapid risk-reduction in suicidal, depressed emergency patients: Clinical trial design and rationale

Sumra Sajid,Ryan E. Lawrence,Hanga C. Galfalvy,John G. Keilp,Vivek K. Moitra,J. John Mann,Michael F. Grunebaum

Journal of Affective Disorders Reports（2024）

Cited 0|Views19

No score

Abstract

•Randomized, midazolam-controlled trial (RCT) of intramuscular (IM) ketamine in suicidal, depressed emergency department (ED) patients.•Outcomes: feasibility, safety, efficacy for reducing suicidality, depression.•Target (N = 90) adults in a major depressive episode warranting hospitalization for suicide risk.•Trial progress (n = 53) shows diverse sample tending towards young adults.

Translated text

Key words

Ketamine,Emergency department,Intramuscular,Suicide,Clinical trial design

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined